Inspire To Submit Additional Data For Dry Eye Treatment
This article was originally published in The Pink Sheet Daily
Executive Summary
Ongoing discussions between the company and FDA regarding diquafosol may take several months, Inspire says.
You may also be interested in...
Allergan Receives Third “Approvable” Letter For Combigan In Intraocular Pressure
Company is counting on a confirmatory trial initiated in 2005 to satisfy FDA concerns regarding the glaucoma treatment.
Allergan Receives Third “Approvable” Letter For Combigan In Intraocular Pressure
Company is counting on a confirmatory trial initiated in 2005 to satisfy FDA concerns regarding the glaucoma treatment.
Inspire Begins Phase III Trial Of Denufosol Tetrasodium For Cystic Fibrosis
The firm must complete the 48-week study before submitting an NDA for inhaled denufosol.